Anti-tissue factor antibodies and compositions

Abstract

Isolated anti-tissue factor antibodies, immunoglobulins, cleavage products and other specified portions and variants thereof having enhanced ADCC activity, as well as anti-tissue factor antibody compositions, encoding or complementary nucleic acids, vectors, host cells, compositions, formulations, devices, transgenic animals, transgenic plants, and methods of making and using thereof. The antibodies of the invention bind human tissue factor and demonstrate enhanced ADCC activity. Accordingly, the antibodies can be used in a variety of methods for diagnosing, treating, and/or preventing diseases involving tissue factor, where enhanced ADCC activity is desirable such as cancer.

1 - 51 . (canceled) 
     
     
         52 . A method of treating a disease selected from pancreatic cancer, colorectal cancer, lung cancer, bladder cancer, and prostate cancer in a subject in need of such treatment comprising administering to the subject a monoclonal antibody which binds tissue factor and comprises the heavy chain amino acid sequence consisting of SEQ ID NO: 2 and the light chain amino acid sequence consisting of SEQ ID NO: 4 in an amount effective to treat the disease. 
     
     
         53 . The method of  claim 52 , wherein the cancer is pancreatic cancer. 
     
     
         54 . The method of  claim 52 , wherein the cancer is colorectal cancer. 
     
     
         55 . The method of  claim 52 , wherein the cancer is lung cancer. 
     
     
         56 . The method of  claim 52 , wherein the cancer is bladder cancer. 
     
     
         57 . The method of  claim 52 , wherein the cancer is prostate cancer. 
     
     
         58 . The method of  claim 52  wherein the antibody is administered in combination concurrently or sequentially with a cytotoxic agent. 
     
     
         59 . The method of  claim 52  wherein the cytotoxic agent is dacarbazine. 
     
     
         60 . The method of  claim 52 , wherein the antibody is conjugated to or formulated with a therapeutic agent. 
     
     
         61 . A method of  claim 52 , further comprising administering, prior, concurrently or after said antibody, at least one composition comprising an effective amount of at least one compound or protein selected from at least one of a detectable label or reporter, an anti-neoplastic agent, a TNF antagonist, an antirheumatic, a muscle relaxant, a narcotic, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, a neuromuscular blocker, an antimicrobial, an antipsoriatic, a corticosteriod, an anabolic steroid, an erythropoietin, an immunization, an immunoglobulin, an immunosuppressive, a growth hormone, a hormone antagonist, a reproductive hormone antagonist, a hormone release modulator, a hormone replacement drug, an antidepressant, an antipsychotic, a stimulant, an asthma medication, a beta agonist, an inhaled steroid, an epinephrine or analog, a cytokine, or a cytokine antagonist. 
     
     
         62 . A method of  claim 52  wherein the antibody is combined with an anti-neoplastic agent selected from a radiopharmaceutical, an estrogen receptor modulator, a retinoid, a topoisomererase inhibitor, a cytotoxin, an alkylating agent, a nitrogen mustard, a nitrosourea, an antimetabolite, a mitotic inhibitor, and a radiosensitizer. 
     
     
         63 . A method according to  claim 62  wherein the anti-neoplastic agent is dacarbazine. 
     
     
         64 . The method of  claim 52 , in which the monoclonal antibody or fragment competes with monoclonal antibody TF8-5G9 for binding to human tissue factor. 
     
     
         65 . The method of  claim 52 , in which the monoclonal antibody is administered intravenously. 
     
     
         66 . The method of  claim 52 , in which the monoclonal antibody is administered in the amount of from 0.05 mg/kg to 12.0 mg/kg body weight. 
     
     
         67 . The method of  claim 52  wherein the antibody is administered in combination concurrently or sequentially with a cytotoxic agent. 
     
     
         68 . The method of  claim 52 , in which the monoclonal antibody binds to human tissue factor integrin subunit with a K D  of 10 −9 M or less. 
     
     
         69 . The method of  claim 62 , in which the wherein the anti-neoplastic agent is a radiopharmaceutical.